Shawshank, VA 5/24/12 (StreetBeat) -- Biopharmaceutical company MediciNova Inc (Nasdaq: MNOV) said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade.
MediciNova, which is testing MN-221 as a treatment for acute asthma attacks not responsive to standard therapy, said the drug failed to show a statistically significant improvement over a placebo.
MN-221 looks to treat the condition by bypassing constricted airways to deliver the drug directly into the lungs. It aims to improve FEV1 ratio when compared with a placebo.
FEV1 ratio measures volume of air exhaled in the first second.
The trial, however, demonstrated a reduction in hospital admissions when MN-221 was added to standard treatments, the company said in a statement.
MediciNova, which said there were three serious adverse events in the trial, plans to continue development of the drug.
Shares in the San Diego, California-based company fell 51 percent to $1.35 in extended trade. They closed at $2.75 on Wednesday on the Nasdaq.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail email@example.com or call (662) 392-0740 for pricing and scheduling.